The diagnostic pathway of Alzheimer's disease in real-world clinical practice in Spain: results from the Adelphi Dementia Disease Specific Programme™
Open Access
- 20 January 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 16, 1702805
Abstract
Introduction: There are challenges associated with the timely diagnosis of people with mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially with the future introduction of amyloid-targeting therapies. This study evaluates the current diagnostic journey for MCI and dementia due to AD in Spain. Methods: This study used data from the Adelphi Real World Dementia Disease Specific Programme (DSP TM ), a cross-sectional survey with retrospective data collection. The survey involved primary care physicians (PCPs) and hospital specialists with experience in managing and treating AD, along with their consulting patients, between January and July 2023 in Spain. Analyses were descriptive. Results: Physicians ( N = 94; 44.7% PCPs, 38.3% neurologists) reported data for 723 patients. Most patients (78.9%) first consulted a PCP. The median (inter-quartile range) time since symptom onset to first consultation was 21.6 (6.1–48.2) weeks and, in those patients who were not diagnosed immediately, the time from first consultation to diagnosis was 13.0 (6.0–21.9) weeks if diagnosed by a PCP, or 28.9 (17.1–52.1) weeks if diagnosed by a specialist. The diagnosing physician was a specialist or a PCP for 83.2% and 16.8% of patients, respectively. In addition, the most used advanced diagnostic techniques were computed tomography scans and magnetic resonance imaging (57.2% and 43.3% of patients, respectively). CSF determination of AD biomarkers was conducted in 12.4% of patients and AD-specific blood biomarkers in 2.9%. Treatment was mostly initiated by neurologists. Conclusion: The diagnostic process for people with MCI and AD could be accelerated by increased awareness of the disease, shorter referral times, and better access to specialized diagnostic services. This study shows limited use of AD-specific biomarker testing in Spain.Keywords
This publication has 50 references indexed in Scilit:
- Diagnostic journey and barriers to diagnosis for patients with mild cognitive impairment or dementia due to Alzheimer’s disease in Canada: results from a real‐world surveyAlzheimer's & Dementia, 2024
- A Systematic Review on the Evidence of Misdiagnosis in Dementia and Its Impact on Accessing Dementia CareInternational Journal of Geriatric Psychiatry, 2024
- Use of Donanemab in Early Symptomatic Alzheimer Disease—ReplyJAMA, 2023
- Amyloid-Targeting Monoclonal Antibodies for Alzheimer DiseaseJAMA, 2023
- Clinically significant anxiety as a risk factor for Alzheimer's disease: Results from a 10‐year follow‐up community studyInternational Journal of Methods in Psychiatric Research, 2023
- Alzheimer's disease diagnosis and management: Perspectives from around the worldAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2022
- Anxiety and depression in Alzheimer’s disease: a systematic review of pathogenetic mechanisms and relation to cognitive declineNeurological Sciences, 2022
- General practitioners’ attitude toward early and pre‐dementia diagnosis of AD in five European countries—A MOPEAD project surveyAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
- Pathways to care for people with dementia: An international multicentre studyInternational Journal of Geriatric Psychiatry, 2019
- Underdiagnosis of Dementia: an Observational Study of Patterns in Diagnosis and Awareness in US Older AdultsJournal of General Internal Medicine, 2018